Eliem Therapeutics Inc (ELYM)
7.38
+0.28
(+3.94%)
USD |
NASDAQ |
May 01, 13:54
Eliem Therapeutics Shareholders Equity (Quarterly): 107.60M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 107.60M |
| September 30, 2023 | 109.74M |
| June 30, 2023 | 112.50M |
| March 31, 2023 | 116.86M |
| December 31, 2022 | 128.72M |
| September 30, 2022 | 134.36M |
| June 30, 2022 | 142.24M |
| Date | Value |
|---|---|
| March 31, 2022 | 155.14M |
| December 31, 2021 | 167.20M |
| September 30, 2021 | 176.66M |
| June 30, 2021 | 101.91M |
| March 31, 2021 | 49.62M |
| December 31, 2020 | 21.57M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
21.57M
Minimum
Dec 2020
176.66M
Maximum
Sep 2021
117.24M
Average
116.86M
Median
Mar 2023
Shareholders Equity (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | 327.94M |
| Candel Therapeutics Inc | 12.74M |
| Lipocine Inc | 20.37M |
| GlycoMimetics Inc | 38.41M |
| Lyell Immunopharma Inc | 654.95M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 110.47M |
| Total Liabilities (Quarterly) | 2.87M |